Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Equifax Q3 revenue, profit rise on mortgage segment growth

Equifax Q3 revenue, profit rise on mortgage segment growth

ReutersReuters2026/10/20 10:39


Overview

  • Global data and analytics provider's Q3 revenue grew 10% yr/yr, meeting analyst expectations

  • Adjusted EPS for Q3 rose 11% and beat analyst expectations

  • Company returned $158 mln to shareholders via buybacks and dividends


Outlook

  • Equifax lowers 2026 full-year revenue guidance midpoint to $6.661 bln due to weak U.S. mortgage market

  • Company expects 2026 adjusted EPS of $8.50, down $0.04 at midpoint from prior guidance

  • Company maintains 2026 Diversified Markets revenue growth guidance at high single-digit percent


Result Drivers

  • DIVERSIFIED MARKETS - Co said broad-based growth across business units drove 8% Diversified Markets revenue increase

  • NEW PRODUCTS - Co attributed record new product Vitality Index of over 17% to innovation in cloud and AI offerings

  • MORTGAGE REVENUE - Co said U.S. Mortgage revenue grew 15% despite challenging market conditions


Company press release: ID:nPn4SS6j3a


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Meet

$1.69 bln

$1.69 bln (18 Analysts)

Q3 Adjusted EPS

Beat

$2.26

$2.20 (20 Analysts)

Q3 EPS

$1.79


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the professional information services peer group is "buy"

  • Wall Street's median 12-month price target for Equifax Inc. is $194.00, about 22.3% above its October 19 closing price of $158.57

  • The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 17 three months ago


Reuters Recommended Reads

  • Oct 19 - Zions Bancorp Q3 EPS rises 20% on improved credit quality

  • Oct 19 - Western Alliance Bancorp Q3 revenue slightly beats estimates, profit rises on wider interest margin

  • Oct 20 - Commerce Bancshares Q3 EPS beats, helped by loan growth


For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected].


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.

Lycia will issue 17.64 million shares at a price of $18 per share to raise $317.5 million.

智通财经•2026/10/23 02:47

Citi is bullish on Palantir (PLTR.US): U.S. government and commercial businesses jointly drive growth, Q3 revenue is expected to exceed expectations again

Citigroup maintains its "Buy" rating on Palantir and raises the target price from $245 to $250.

智通财经•2026/10/23 02:47
Citi is bullish on Palantir (PLTR.US): U.S. government and commercial businesses jointly drive growth, Q3 revenue is expected to exceed expectations again

Despite its stock price being halved, Goldman Sachs maintains a Buy rating: Holding $10 billions in orders, CoreWeave (CRWV) faces a major test with several billions in financing

As a core manufacturer of AI computing power infrastructure, CoreWeave (CRWV.US) holds orders worth tens of billions and its business is expanding rapidly. However, capital expenditure pressure and financing gaps have become the main concerns of the market.

智通财经•2026/10/23 02:19
Despite its stock price being halved, Goldman Sachs maintains a Buy rating: Holding $10 billions in orders, CoreWeave (CRWV) faces a major test with several billions in financing